Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Simms

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
Arthritis Research & Therapy|February 25, 2014
Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label studyAvram Goldberg, Thomas Geppert, Elena Schiopu, et al.
Blood|October 1, 1996
Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patientsR L Comenzo, E Vosburgh, R W Simms, et al.
Arthritis Research & Therapy|February 8, 2019
Microbiome dysbiosis is associated with disease duration and increased inflammatory gene expression in systemic sclerosis skinMichael E Johnson, Jennifer M Franks, Guoshuai Cai, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 5, 2015
A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosisLisa M Rice, Jessica Ziemek, Eric A Stratton, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 3, 2024
Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm TrialGeorge E Georges, Dinesh Khanna, Mark H Wener, et al.
Annals of the Rheumatic Diseases|May 9, 2007
Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosisPhilip J Clements, Michael D Roth, Robert Elashoff, et al.
Arthritis and Rheumatism|June 3, 2008
A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase diseaseArnold E Postlethwaite, Weng Kee Wong, Philip Clements, et al.
Arthritis Research & Therapy|July 6, 2016
miR-155 in the progression of lung fibrosis in systemic sclerosisRomy B Christmann, Alicia Wooten, Percival Sampaio-Barros, et al.
Arthritis and Rheumatism|October 2, 2002
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenonPeter A Merkel, Karen Herlyn, Richard W Martin, et al.
Arthritis and Rheumatism|April 29, 1998
Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind studyF M Wigley, J H Korn, M E Csuka, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Arthritis Research & Therapy|February 25, 2014
Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label studyAvram Goldberg, Thomas Geppert, Elena Schiopu, et al.
Blood|October 1, 1996
Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patientsR L Comenzo, E Vosburgh, R W Simms, et al.
Arthritis Research & Therapy|February 8, 2019
Microbiome dysbiosis is associated with disease duration and increased inflammatory gene expression in systemic sclerosis skinMichael E Johnson, Jennifer M Franks, Guoshuai Cai, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 5, 2015
A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosisLisa M Rice, Jessica Ziemek, Eric A Stratton, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 3, 2024
Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm TrialGeorge E Georges, Dinesh Khanna, Mark H Wener, et al.
Annals of the Rheumatic Diseases|May 9, 2007
Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosisPhilip J Clements, Michael D Roth, Robert Elashoff, et al.
Arthritis and Rheumatism|June 3, 2008
A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase diseaseArnold E Postlethwaite, Weng Kee Wong, Philip Clements, et al.
Arthritis Research & Therapy|July 6, 2016
miR-155 in the progression of lung fibrosis in systemic sclerosisRomy B Christmann, Alicia Wooten, Percival Sampaio-Barros, et al.
Arthritis and Rheumatism|October 2, 2002
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenonPeter A Merkel, Karen Herlyn, Richard W Martin, et al.
Arthritis and Rheumatism|April 29, 1998
Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind studyF M Wigley, J H Korn, M E Csuka, et al.
Pageof 8